BioNexus Gene Lab Corp financial data

Symbol
BGLC on Nasdaq
Location
10 2 Tower B, Vertical Business Suite,, 8 Jalan Kerinchi,, Kuala Lumpur, Malaysia
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 18, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 410 % -18.3%
Quick Ratio 77.4 % +13.5%
Debt-to-equity 22.2 % +21.3%
Return On Equity -35.6 % -52.6%
Return On Assets -29.1 % -48.9%
Operating Margin -31.2 % -37.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.8M shares
Common Stock, Shares, Outstanding 1.8M shares -89.8%
Entity Public Float 8.16M USD -87.7%
Common Stock, Value, Issued 17.3M USD +0.82%
Weighted Average Number of Shares Outstanding, Diluted 1.8M shares +1.69%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 9.55M USD +4.01%
Cost of Revenue 8.2M USD +3.74%
Research and Development Expense 12.6K USD +53.2%
Selling and Marketing Expense 608K USD +346%
General and Administrative Expense 2.01M USD +1.75%
Operating Income (Loss) -2.98M USD -42.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3.01M USD -42.6%
Income Tax Expense (Benefit) -39K USD -379%
Net Income (Loss) Attributable to Parent -2.93M USD -33%
Earnings Per Share, Diluted -0.34 USD/shares -407%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current 1.85M USD
Inventory, Net 1.22M USD +17.7%
Assets, Current 6.38M USD -18.7%
Property, Plant and Equipment, Net 1.59M USD +18.2%
Operating Lease, Right-of-Use Asset 200K USD -17.1%
Assets 9.42M USD -15.4%
Accounts Payable, Current 1.18M USD -17.2%
Liabilities, Current 1.76M USD +25.6%
Deferred Income Tax Liabilities, Net 0 USD -100%
Operating Lease, Liability, Noncurrent 141K USD -22.6%
Liabilities 1.9M USD +19.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -116K USD +86.9%
Retained Earnings (Accumulated Deficit) -4.68M USD -168%
Stockholders' Equity Attributable to Parent 7.52M USD -21.2%
Liabilities and Equity 9.42M USD -15.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -824K USD -2118%
Net Cash Provided by (Used in) Financing Activities -860 USD -103%
Net Cash Provided by (Used in) Investing Activities -15.6K USD -529%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 1.8M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -798K USD -909%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 814K USD -85%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.55K USD -43%
Operating Lease, Liability 197K USD
Depreciation 26.6K USD +32.3%
Payments to Acquire Property, Plant, and Equipment 9.05K USD -58.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -2.16M USD +6.24%
Property, Plant and Equipment, Gross 2.54M USD +9.98%
Operating Lease, Liability, Current 55.8K USD +4.88%
Deferred Income Tax Expense (Benefit) 16K USD +886%
Preferred Stock, Shares Authorized 30M shares 0%
Additional Paid in Capital -5.01M USD 0%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 66.9K USD
Operating Leases, Future Minimum Payments Due, Next Twelve Months 0 USD
Operating Leases, Future Minimum Payments, Due in Three Years 62.2K USD
Operating Leases, Future Minimum Payments Due 220K USD
Interest Expense 6.19K USD +45.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares